Stock Rating Downgrade
The Value Trend Rating for Bristol-Myers Squibb Co (NYSE: BMY) weakened in recent days from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
On 10/1/25, Bristol-Myers Squibb Co (NYSE: BMY) stock enjoyed a very large increase of 5.2%, closing at $47.43. Moreover, exceptionally high trading volume at 270% of normal accompanied the advance. The stock has risen 5.6% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Bristol-Myers Squibb has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Bristol-Myers Squibb has a slightly positive Appreciation Score of 70 but a poor Power Rating of 19, leading to the Negative Value Trend Rating.
Be the first to comment